

TRIMEDYNE COMMENCES MARKETING NEW SIDE-FIRING LASER DEVICE

FOR IMMEDIATE RELEASE

CONTACT: Craig Smith
(949) 951-3800, Ext. 288
csmith@trimedyne.com

September 6, 2005 – Irvine, CA: TRIMEDYNE, INC. (OTCBB “TMED”) today announced it has begun marketing its new VaporMAX™ Side-Firing Laser Device for use with its high power, 80 watt Holmium Laser for the treatment of Benign Prostatic Hyperplasia (BPH), commonly referred to as an enlarged prostate. This condition affects about 50% of men over age 55, and an estimated 200,000 procedures are performed to treat BPH each year in the United States.

Trimedyne’s VaporMAX™ Device vaporizes tissue faster than other currently marketed side-firing laser devices, based on animal tissue laboratory testing and published data, minimizing procedure and costly operating room time. In addition, testing has shown Trimedyne’s VaporMAX™ Device to be more durable than other side-firing devices, enabling even large prostates to be treated with just one VaporMAX™ Device, further reducing the cost of the procedure. Trimedyne’s VaporMAX™ Device qualifies for the new, higher Medicare reimbursement rate under Ambulatory Payment Classification Code 2525, which makes its use desirable by hospitals and physicians.

Trimedyne presently has a backlog of \$75,000 of orders for its VaporMAX™ Device, all of which are expected to be filled in the quarter ending September 30, 2005.

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, financial and other information, visit Trimedyne's website, <http://www.trimedyne.com>.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

* * * *